This study determined the mass balance and pharmacokinetics of edoxaban in humans after oral administration of [ 14 C]-edoxaban. After oral administration of 60 mg (as active moiety) of [ 14 C]-edoxaban to six healthy male subjects, serial blood/plasma, and urinary and fecal samples were collected for up to 168 h post-dose. All samples were analyzed for total radioactivity by liquid scintillation counting and for concentrations of edoxaban and four metabolites in plasma, urine, and fecal samples by either high-performance liquid chromatography/tandem mass spectrometry method using multiple reaction mode or a liquid chromatography radiometric method. The mean recovery of radioactivity was >97% of the administered radioactive dose, with 62.2% eliminated in feces and 35.4% in urine. Unchanged edoxaban accounted for the majority of radioactivity, with 49.1 and 23.8% of the dose as parent observed in feces and urine, respectively. Unchanged edoxaban was the most abundant species in plasma with a mean AUC 0-∞ of 1596 ng·h/ml. The next most abundant species was metabolite M4 with a mean AUC 0-∞ 147 ng·h/ml. The mass balance of edoxaban was well described with unchanged edoxaban as the most abundant component of total radioactivity. Edoxaban is eliminated through multiple pathways, but each accounts for only a small amount of overall elimination.
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Introduction
Nonvalvular atrial fibrillation, which increases the risk of ischemic stroke and venous thromboembolism (Thomas and Lerman, 2011; Olesen et al., 2011) , are major medical issues associated with significant morbidity and mortality (Cohen et al., 2007) . Patients with these thrombotic disorders generally require extended thromboprophylaxis, which currently includes warfarin, despite its many limitations (Fuster, et al., 2011) . Factor Xa (FXa) is a target for new anticoagulants and is located at the junction of the intrinsic and extrinsic pathways of coagulation. Free FXa is responsible for the generation of the first trace amounts of thrombin, and FXa within the prothrombinase complex (bound to the surface of activated platelets) induces the propagation phase of thrombin generation from prothrombin (Rai et al., 2001; Weitz, 2011) .
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Materials and Methods
Study Design. This was a single center, open-label, nonrandomized study with the administration of radiolabeled edoxaban to six healthy male subjects to determine the PK of the parent drug and known metabolites and to identify potential unknown metabolites. The study was conducted at Charles River Clinical Services (Edinburgh, UK). The study followed the guidelines of the World Medical Association Declaration of Helsinki in its revised edition, the guidelines for current Good Clinical Practice, the requirements of Directive 2001/20/EC2 and the corresponding UK statutory instrument, as well as the demands of national drug and data protection laws and other applicable regulatory requirements. All subjects provided written informed consent. 144, and 168 h post-dose. Each blood sample was gently mixed and approximately 10 mL of the 12 ml were placed into a lithium heparin tube. After centrifugation at 1500g for 10 min at approximately 4°C, the separated plasma was transferred into two polypropylene tubes: an aliquot for total radioactivity and an aliquot for measurement of edoxaban and metabolites. The remaining 2 ml of whole blood from the 12 ml sample was placed into a 2 ml lithium heparin tube and stored at approximately 2° to 8°C until analyzed for total radioactivity. Additional 25 ml blood samples were collected at 0 (predose), 1, 2, 4, 8, 12, 24, 48, 72 , and 96 h post-dose for metabolite profiling. Urine samples were collected and pooled at 0 (predose), 0-4, 4-8, 8-12, 12-24, 24-36, 36-48, 48-72, 72-96, 96-120, 120-144 , and 144-168 h post-dose. Four 20 ml samples were aliquoted from pooled and weighed total volume at each timepoint. Fecal samples were collected and pooled at 0 (predose), 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 h post-dose. Fecal homogenates (2 × ~50 g) were obtained from total pooled and weighed samples collected at each timepoint.
Subjects
Radiometric Analysis of Edoxaban and Metabolites. All samples were processed appropriately and radioactive contents of extracts were determined using duplicate aliquots. The aliquots were admixed with scintillation fluid, and subjected to liquid scintillation counting for 5 min together with representative blank samples, using a liquid scintillation analyzer with automatic quench correction by an external standard method. The lower limit of detection was 30 dpm above background. Recovery of radioactivity in urine and feces collected from each subject during the course of the trial was calculated as percent of dose administered, and cumulative recovery of radioactivity was determined. Radioactivity concentrations in whole This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Subjects. Eleven subjects were screened for the trial; six were enrolled and all completed the study. The mean (standard deviation [SD] ) age of the subjects was 38.5 (4.9) years. The mean (SD) body weight at screening was 85.0 (5.6) kg and body mass index ranged from 25.0 to 28.8 kg/m 2 . All six subjects were Caucasian males.
Absorption of Radioactivity.
The maximum concentration of total radioactivity was observed at 0.5 h post-dose in five of the six subjects and at 1.0 h post-dose in the remaining subject in both plasma and whole blood, indicating rapid absorption of [ 14 C]-edoxaban. The PK parameters for total radioactivity are summarized in Table 1 . The cumulative urinary, fecal, and total radioactivity versus time are shown in Fig. 2 . The mean (range) total radioactivity recovered in urine and feces was 97.6% (92.5-102.1%) at 168 h post-dose ( Table 2 ). The mean cumulative radioactivity excreted in feces was 62.2% (55.2-73.0%), accounting for the majority of total radioactivity. The mean cumulative urinary radioactivity was 35.4% (27.4-46.9%) of the administered dose at 168 h post-dose. By 72 h post-dose, 85% of the total radioactivity had been excreted either in feces or urine.
The ratios of plasma edoxaban AUC to total radioactivity were close to unity, suggesting that most of the radiolabeled moiety persisted as parent drug. In whole blood, approximately 40% of the total radioactivity was associated with the cellular component.
This article has not been copyedited and formatted. The final version may differ from this version. represented <2% of total radioactivity. The most abundant metabolite detected in urine was M1, which represented a mean of 1.85% of total radioactivity collected over the 168 h study period.
Therefore, a quantitative method was developed to measure urinary edoxaban concentrations.
The measured urine edoxaban concentrations versus time indicate that the majority of edoxaban is eliminated renally within 24 h. The mean (SD) cumulative amount of edoxaban detected in urine was 22.6 (±5.2) mg with an estimated median renal clearance of 12.7 l/h.
Edoxaban was also the predominant excreted component in feces (Table 2) , accounting for 49.1% of the administered dose. The other identified peaks were M4, M6, and M8, with other more minor peaks observed. Each fecal metabolite represented <2% of total radioactivity. Due to these low radioactivity measures, the ratios of the metabolites to parent concentrations could not be determined.
Plasma Pharmacokinetics of Edoxaban and Its Metabolites. Plasma concentrations of
edoxaban and its metabolites versus time course are shown in Fig. 3 . Plasma edoxaban is the predominant species and shows a rapid peak with biexponential decline (Fig. 3A) . The plasma metabolite concentrations follow the time course of the parent drug, albeit at much lower plasma concentrations. The most abundant plasma metabolite was M4 followed by M1 and M6, all with Slightly greater total systemic exposure (based on AUC) to total radioactivity was observed in plasma compared with whole blood, and an estimated 40% of the radioactivity was associated with the cellular component of whole blood. The mean plasma exposure and terminal elimination half-life values were similar to those reported for unlabeled drug in prior studies (Mendell et al., 2011; Ogata et al., 2010) .
In summary, the mass balance of edoxaban was well characterized in this study with nearly complete recovery of the total radioactivity. Unchanged edoxaban was the most abundant species in plasma, urine, and feces, with modest metabolism (<25% total dose) that occurs primarily through hydrolysis. Edoxaban is eliminated through multiple elimination pathways including renal excretion, biliary excretion, and metabolism.
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Footnotes
Dr Bathala has since retired from Daiichi Sankyo.
Meeting abstracts where the work was previously presented: 
